



All

Images

Videos

翻译成中文

开启取词

21,400 Results

Any time ▼

Treatment of unresectable intrahepatic cholangiocarcinoma ...

www.ncbi.nlm.nih.gov › ... › Elsevier Sponsored Documents

Treatment of unresectable intrahepatic **cholangiocarcinoma** with yttrium-90 radioembolization: A systematic review and pooled analysis ... future randomized trials comparing systemic chemotherapy, TACE and local **radiation** will be required to identify the optimal treatment modality for unresectable ICC. ... Wasan H., Palmer D.H. **Cisplatin plus** ...

Cited by: 66

Author: Dp Al-Adra, Rs Gill, Sj Axford, X Shi, N K...

Publish Year: 2015

Transcatheter arterial chemoembolization or chemoinfusion ...

onlinelibrary.wiley.com/doi/10.1002/cncr.23787/full

From 1997 to 2007, 49 patients with unresectable ICC were treated with TACE (n = 124) or transcatheter arterial chemoinfusion (TACI) (n = 96). Tumor response was evaluated based on computed tomography scans obtained 1 month to 3 months after TACE or TACI.

Published in: **Cancer** · 2008

Authors: Jin Hyoung Kim · Hyunki Yoon · Kyubo Sung · Giyoung Ko · Dong Il Gwon · Ji Hoon S...

Affiliation: University of Ulsan

About: Transcatheter arterial chemoembolization · Circulatory system · Blood vessel · Intrahe...

Treatment of Unresectable Cholangiocarcinoma with ...

<https://link.springer.com/article/10.1007/s11605-007-0312-y> ▼

Transcatheter arterial chemoembolization (TACE) has been shown to prolong survival in **hepatocellular carcinoma** patients, but experience using TACE in the **treatment** of **cholangiocarcinoma** is limited. We report our experience treating **cholangiocarcinoma** with TACE using **chemotherapeutic regimens based** on the well-tolerated **drug gemcitabine**.

Cited by: 108

Author: Niraj J. Gusani, Fady K. Balaa, Jennifer L...

Publish Year: 2008

Transarterial Therapies for the Treatment of Intrahepatic ...

www.ncbi.nlm.nih.gov › ... › v.30(1); 2013 Mar

This article discusses the current role of transarterial therapies in the treatment of intrahepatic **cholangiocarcinoma**. Keywords ... was 9.1 months, with **combination gemcitabine-cisplatin** TACE showing improved survival over ... for unresectable intrahepatic **cholangiocarcinoma**: **clinical efficacy** and factors influencing outcomes. ...

Cited by: 7

Author: Joseph J. Zechlinski, William S. Rilling

Publish Year: 2013

Name of journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 46910

Manuscript Type: ORIGINAL ARTICLE

Retrospective Cohort Study

Clinical efficacy of transcatheter arterial chemoembolization combined with radiotherapy based on gemcitabine plus cisplatin in hilar cholangiocarcinoma

Zheng WH *et al.* TACE combined with radiotherapy in hilar cholangiocarcinoma

Wen-Heng Zheng, Tao Yu, Ya-Hong Luo, Ying Wang, Ye-Fu Liu, Xiang-Dong

Match Overview

1 match

1	Internet 20 words crawled on 20-May-2018 www.spandidos-publications.com	1%
2	Internet 20 words crawled on 23-Mar-2016 www.medicaljournals.se	1%
3	Internet 19 words crawled on 10-May-2019 article.nursingscience.net	1%
4	Internet 10 words crawled on 08-Feb-2019 www.hnykdxb.com	<1%



国内版

国际版

Clinical efficacy of TACE combined with radiotherapy based on gemcitabine plus ci



All

Images

Videos

翻译成中文

关闭取词

24,300 Results

Any time ▾

Treatment of unresectable intrahepatic cholangiocarcinoma ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316196>

Introduction. Intrahepatic **cholangiocarcinoma** (ICC) is a malignant transformation of cholangiocytes within the hepatic parenchyma. The incidence of this primary liver malignancy is increasing, 1,2 and ICC accounts for up to 15% of primary liver cancers. 3 In contrast to the other two locations of **cholangiocarcinoma** (hilar and distal bile duct), intrahepatic lesions are often asymptomatic and ...

Cited by: 67

Author: Dp Al-Adra, Rs Gill, Sj Axford, X Shi, N K...

Publish Year: 2015

Transcatheter arterial chemoembolization with gemcitabine ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360827>

Mar 09, 2015 · Overall survival was 8.4 months (95% CI 6.2–10.7) in the **gemcitabine plus cisplatin group** and 7.6 months (95% CI 6.8–8.7) in the **capecitabine plus cisplatin group** (P=0.024). Based on these results, the **combination of gemcitabine plus cisplatin** (or **oxaliplatin** as a potentially better tolerated agent) is considered to be the standard of care as the first-line regimen for BTC.

Author: Qing Zhao, Sheng Qian, Liang Zhu, Xu...

Publish Year: 2015

Transcatheter arterial chemoembolization or chemoinfusion ...

<https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.23787>

The aim of the study was to evaluate the **clinical efficacy of TACE** or TACI in patients with unresectable ICC and to identify prognostic factors associated with **clinical** success. METHODS. From 1997 to 2007, 49 patients with unresectable ICC were treated with TACE (n = 124) or transcatheter arterial chemoinfusion (TACI) (n = 96).

Cited by: 116

Author: Jin Hyoung Kim, Hyun-Ki Yoon, Kyu-Bo ...

Publish Year: 2008

Gemcitabine plus cisplatin versus chemoradiotherapy in ...

<https://www.sciencedirect.com/science/article/pii/S0959804914009071>

In conclusion, conventional **radiotherapy** with 50 Gy **combined** to 5-fluorouracil and **cisplatin** is not superior to a chemotherapy regimen with **gemcitabine** and oxaliplatin in locally-advanced non-resectable biliary duct cancers. Chemotherapy **based on gemcitabine** and a platinum compound must be selected for **clinical** practice outside of **clinical** trials.

Cited by: 8

Author: Jean-Marc Phelip, Véronique Vendrely, FI...

Publish Year: 2014

Hilar Cholangiocarcinoma: expert consensus statement ...

<https://www.sciencedirect.com/science/article/pii/S1365182X15312478>